ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer
นักวิจัย : Chitapanarux I. , Chitapanarux T. , Tharavichitkul E. , Mayurasakorn S. , Siriwittayakorn P. , Yamada S. , Lorvidhaya V.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2554
อ้างอิง : 18235530 , 10.2349/biij.7.4.e25 , http://www.scopus.com/inward/record.url?eid=2-s2.0-83455220049&partnerID=40&md5=538b3076f330acc5e7fc1d8cd7c8f095 , http://www.ncbi.nlm.nih.gov/pubmed/22279502 , http://cmuir.cmu.ac.th/handle/6653943832/2957
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Objective: To evaluate the activity and safety of adding oxaliplatin to a standard chemoradiotherapy schema, including 5-fluorouracil (5-FU)/folinic acid (FA), in locally-advanced rectal cancer (LARC). Methods: Two cycles of oxaliplatin 130 mg/m2 plus FA 20 mg/m2 bolus for 5 days and 5-FU 350 mg/m2 continuous infusion for 5 days were given during week 1 and 4 of pelvic radiotherapy 46 Gy. Patients with a T3/4 and/or node-positive rectal tumour were eligible. Surgery was performed 4-6 weeks after radiotherapy. The primary endpoint was to determine the rate of pathological response. Secondary endpoints were to assess the rate of clinical response and the safety profile. Results: Between March 2005 and January 2009, a total of 35 patients were enrolled. The pathological downstaging rate was 79% with a pathological complete response rate of 17%. The overall clinical response rate (assessed by computed tomography or transrectal ultrasound) was 77%. Grade 3 diarrhoea and Grade 3 neutropaenia were reported in 14% and 11% of the patients, respectively. Eleven patients did not undergo surgery: four of them refused the operation, and seven patients were inoperable due to disease progression. In 24 patients who had surgery, a sphincter-preserving procedure could be performed in 29%. At the median follow-up time of 28.1 months, 25 patients (71%) survived with no evidence of disease. Conclusion: The promising results in terms of pathological response, and the associated good safety profile of a regimen of oxaliplatin plus 5-FU/FA with concomitant radiotherapy, suggest that the regimen could be used in LARC. © 2011 Biomedical Imaging and Intervention Journal. All rights reserved.

บรรณานุกรม :
Chitapanarux I. , Chitapanarux T. , Tharavichitkul E. , Mayurasakorn S. , Siriwittayakorn P. , Yamada S. , Lorvidhaya V. . (2554). A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Chitapanarux I. , Chitapanarux T. , Tharavichitkul E. , Mayurasakorn S. , Siriwittayakorn P. , Yamada S. , Lorvidhaya V. . 2554. "A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Chitapanarux I. , Chitapanarux T. , Tharavichitkul E. , Mayurasakorn S. , Siriwittayakorn P. , Yamada S. , Lorvidhaya V. . "A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2554. Print.
Chitapanarux I. , Chitapanarux T. , Tharavichitkul E. , Mayurasakorn S. , Siriwittayakorn P. , Yamada S. , Lorvidhaya V. . A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2554.